Thermo Fisher Scientific Inc (TMO) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Strong Start in Core Business for Thermo Fisher in Q1

Regional Director Alex Morozov

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA | Apr 28, 2022

Wide-moat Thermo Fisher Scientific kicked off 2021 with strong results across most segments, allowing the company to materially raise its revenue and earnings guidance for the full year. We are updating our model and expecting a modest raise in our fair value estimate, but we anticipate shares still trading at a premium to our valuation.

Read Full Analysis

Thermo Fisher Scientific Inc's Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).

Contact

168 Third Avenue
Waltham, MA, 02451

T +1 781 622-1000

investorrelations@thermofisher.com

www.thermofisher.com

Sector Healthcare

Industry Diagnostics & Research

Most Recent Earnings Mar 31, 2022

Fiscal Year End Dec 31, 2022

Stock Type Aggressive Growth

Employees 130,000

Thermo Fisher Scientific Inc's Related Articles & News

21 Best Healthcare Companies to Invest In

These companies largely earn their competitive advantage from intangible assets and their stocks are great choices for an investor’s watchlist.

Benjamin Slupecki

29 Stock Funds That Flip-Flopped in the Rankings

These funds moved from best to worst, or from worst to best, amid the stock market's volatility.

Katherine Lynch

12 Overvalued Mega-Cap Stocks to Avoid

After a decade of outperformance, these mega-cap stocks are significantly overvalued today.

11 Top Stocks for 2022 and Beyond

These wide-moat companies have positive moat trends and exemplary capital allocation ratings.

Susan Dziubinski

Sustainability Matters

How Did Large-Cap Sustainable Stock Funds Perform in Q3?

Stock-pickers led the way, particularly high-conviction funds.

The Winners of the New Definition of Infrastructure

Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Buys and Sells

Funds focus purchases in basic materials and consumer sectors.

Stock Strategist Industry Reports

Coronavirus Vaccine Progress Accelerates

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Buys and Sells

Stock-pickers find value in times of volatility and continue to purchase and hold high-quality names.

The Morningstar Ultimate Stock-Pickers Team

Premium Article

Stocks for the Next Decade

The future's bright for these 29 companies. Grab the shades.

Susan Dziubinski

Stock Strategist

Leader in Genomic Sequencing Illuminates the Way

Continued technology advancements and market expansion support Illumina's narrow moat.

Michael Waterhouse

Investing Specialists

Top 10 Buys and Sells by the Ultimate Stock-Pickers

A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

The Morningstar Ultimate Stock-Pickers Team

Fund Spy: Morningstar Medalist Edition

Announcing the Morningstar Fund Managers of the Year for 2013

Remarkable performances amid a remarkable year.

Credit Insights

Payrolls Not Too Hot, Not Too Cold

It appears that the corporate-bond market believes Friday's jobs report was high enough to suggest an advancing economy, but not so strong as to prompt a Fed taper.

Stuck in the Middle Not a Bad Place to Be With These Funds

A handful of analyst-recommended moderate-allocation funds have proved their mettle in good times and bad.

Credit Insights

Credit Spreads Remain Range-Bound

We are seeing an increase in idiosyncratic catalysts that are specific to an individual issuer as opposed to industry factors that affect an entire sector.

Quarter-End Insights

Our Outlook for the Credit Markets

Widening investment-grade credit spreads and rising interest rates lead to losses.

Stocks Attractive on a Relative, But Not Absolute, Basis

Investors should keep their expectations in check with few asset classes looking particularly attractive and complacency in the marketplace, says Allocation Fund Manager of the Year David Giroux of T. Rowe Price Capital Appreciation.

Announcing Morningstar's Fund Managers of the Year for 2012

These skippers shone amid a challenging market environment.

Are Equity Fair Values Teetering on the 'Cliff'?

A lot of companies are very well positioned regardless of how the fiscal cliff gets resolved, as long as it gets resolved, says Morningstar's Heather Brilliant.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.